LONDON (Alliance News) - Drugmaker GlaxoSmithKline PLC on Wednesday said it has signed a strategic collaboration agreement with Miltenyi Biotec, a Germany-based biotechnology firm.
Under the deal, Glaxo will combine its cell and gene therapy-based treatment developments with the cell processing and other cell therapy capabilities of Miltenyi. No financial details on the agreement were disclosed.
"Cell based gene therapies are living treatments, unique to individual patients and complex to manufacture. We see tremendous potential for the cell and gene therapy platform we are building within GSK. However the complexity of current manufacturing processes limits their use to local treatment of small patient populations," said Patrick Vallance, president of pharmaceuticals research and development at Glaxo.
"Working with Miltenyi Biotec, our vision is to transform current technology so that we can expand the possibilities for cell and gene therapy treatment to wider patient populations with broader geographical reach," he added.
Glaxo shares were down 0.6% to 1,407.00 pence on Wednesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.